MedTrace Logo

Autologous Mesenchymal Stem Cell Transplantation in Cirrhosis Patients With Refractory Ascites

NCT01854125 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-05-15

No results posted yet for this study

Summary

Liver cirrhosis (LC) is the final destiny in chronic liver disease.The quality of life in liver cirrhosis patients with refractory ascites are very wretched. The objective of this study is to evaluate the therapeutic efficacy of autologous bone marrow mesenchymal stem cells (BMSCs) transplantation via liver artery in Child-Pugh B and C stage of liver cirrhosis patients with refractory ascites. The immunomodulatory impact of MSCs in fibrosis was confirmed, and several clinical studies have applied MSCs to eliminate the progression of fibrosis. In this research the investigators will study the affect and influence of MSCs in the patients,include assay of liver function,variation of ascites,Child-Pugh score etc.

Conditions

  • Immune Function in Blood
  • Liver Function in Blood
  • Variation of Ascites
  • Characters of Quality of Life
  • Child-Pugh Score

Interventions

BIOLOGICAL

autologous bone marrow mesenchymal stem cells transplantation

Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.

BIOLOGICAL

autologous bone marrow msenchymal stem cells transplantation

Sponsors & Collaborators

  • Nanjing PLA General Hospital

    lead OTHER

Principal Investigators

  • Fangyu Wang, MD/PhD · Nanjing University

  • Fangyu Wang, MD/PhD · Nanjin University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01854125 on ClinicalTrials.gov